Coda’s chemogenetics convinces investors to re-up in series A extension

Coda raised $15M in a series A extension to begin testing its chemogenetic therapies in animals

Cellular data for Coda’s chemogenetic therapy convinced its existing investors to back a $15 million extension of the company’s series A round, which will enable the biotech to generate in vivo data and choose clinical candidates for neuropathic pain and focal epilepsy.


Read the full 420 word article

User Sign In